Abstract
Gliptins: A new class of oral antidiabetic agents
Department of Endocrinology, Diabetes and Metabolism, Sri Ramachandra University, Porur, Chennai-600 116, India
Correspondence Address:
K G Seshadri Department of Endocrinology, Diabetes and Metabolism, Sri Ramachandra University, Porur, Chennai-600 116 India krishnagseshadri@gmail.com
India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for alternative therapies that can overcome the limitations associated with conventional antidiabetic agents. This review focuses on Gliptins, which have become a research area of intense focus and present an alternative therapeutic strategy for patients with type 2 diabetes. Gliptins show significant improvements in glycaemic control and are well tolerated, particularly with regard to weight change and hypoglycemia. Hence, gliptins are considered as useful agents for the treatment of type 2 diabetes mellitus.
